Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with Re-Induction Chemotherapy for Relapsed ALL and Lymphoblastic Lymphoma
NCT00873093Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2009
- Primary completion
- Sep 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of bortezomib in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by National Cancer Institute. Started Mar 2009; status: completed.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00873093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00873093.